Twist Bioscience’s (NASDAQ:TWST) quiet period will expire on Monday, December 10th. Twist Bioscience had issued 5,000,000 shares in its IPO on October 31st. The total size of the offering was $70,000,000 based on an initial share price of $14.00. During Twist Bioscience’s quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
TWST has been the subject of a number of recent analyst reports. Robert W. Baird initiated coverage on shares of Twist Bioscience in a research report on Monday, November 26th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. initiated coverage on shares of Twist Bioscience in a research report on Monday, November 26th. They issued a “neutral” rating and a $27.00 price objective for the company. Finally, Cowen initiated coverage on shares of Twist Bioscience in a research report on Monday, November 26th. They issued an “outperform” rating for the company.
Shares of NASDAQ:TWST opened at $31.08 on Friday. Twist Bioscience has a 52 week low of $12.38 and a 52 week high of $34.46.
In related news, Director Keith Crandell bought 75,000 shares of the company’s stock in a transaction on Friday, November 2nd. The stock was bought at an average cost of $14.00 per share, with a total value of $1,050,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
COPYRIGHT VIOLATION WARNING: “Twist Bioscience Corporation’s Quiet Period Will Expire on December 10th (NASDAQ:TWST)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/12/07/twist-bioscience-corporations-quiet-period-will-expire-on-december-10th-nasdaqtwst.html.
Twist Bioscience Company Profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Read More: How analysts view the yield curve
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.